NCT03278782 - Study of Pembrolizumab (MK-3475) in Combination With Romidepsin | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 14, 2017

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions

Recurrent Anaplastic Large Cell LymphomaRecurrent Angioimmunoblastic T-Cell LymphomaRecurrent Mature T- and NK-Cell Non-Hodgkin LymphomaRecurrent Mycosis FungoidesRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Anaplastic Large Cell LymphomaRefractory Angioimmunoblastic T-Cell LymphomaRefractory Mature T-Cell and NK-Cell Non-Hodgkin LymphomaRefractory Mycosis FungoidesRefractory Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedRefractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

Interventions

BIOLOGICAL

Pembrolizumab

Given IV

DRUG

Romidepsin

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER